TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line

Gene

Volumn 229, Issue 1-2, 1999, Pages 75-81

  Duan, Zhenfeng ^a   Feller, Aynn J ^a   Toh, Han Chong ^a   Makastorsis, Thomas ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Differential display; Drug resistance; Genetics; MRNA expression

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DOXORUBICIN; MESSENGER RNA; PACLITAXEL; VERAPAMIL;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; BASE SEQUENCE; CLONING, MOLECULAR; DOXORUBICIN; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033580453     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(99)00042-6     Document Type: Article

References (15)

1. Abbaszadegan M.R., Foley N.E., Gleason-Guzman M.C., Dalton W. S. Resistance to the chemosensitizer verapamil in a multi-drug resistant (MDR) human multiple myeloma cell line. Int. J. Cancer. 66:1996;506-514.
2. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
3. Casazza A.M., Fairchild C.R. Paclitaxel (Taxol): mechanisms of resistance. Cancer Treat. Res. 87:1996;149-171.
4. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T.M., Fojo T., Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125.
5. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
6. Haber M., Burkhart C.A., Regl D.L., Madafiglio J., Norris M.D., Horwitz S. B. Altered expression of Mβ2, the class II β-tubulin isotype, in murine J774.2 cell line with a high level of Taxol resistance. J. Biol. Chem. 270:1995;31269-31275.
7. Horwitz S.B., Cohen D., Rao S., Ringel I., Shen H.J., Yang C.P. Taxol: mechanisms of action and resistance. Monogr. Natl. Cancer Inst. 15:1993;55-61.
8. Johnson D.H., Paul D.M., Hande K.R., Shyr Y., Blanke C., Murphy B., Lewis M., DeVore R.F. Paclitaxel plus carboplatin in advanced non-small-cell-lung-cancer: a phase II trial. J. Clin. Oncol. 14:1996;2054-2060.
9. Lanni J.S., Lowe S.W., Licitra E.J., Liu J.O., Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA. 18:1994;9679-9683.
10. Liang P., Pardee A.B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 257:1992;967-971.
11. Liang P., Averboukh L., Pardee A.B. Distribution and cloning of eukaryotic mRNAs by means of differential display: refinements and optimization. Nucleic Acids Res. 21:1993;3269-3275.
12. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl. J. Med. 334:1996;1-6.
13. Scheffer G.L., Wijngaard P.L.J., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J.L.M., Clevers H.C., Scheper R.J. The drug resistance-related protein Lrp is the human major vault protein. Nat. Med. 1:1995;578-582.
14. van der Zee A.G.J., Hollema H.H., Bruijn H.W.A., Willemse P.H.B., Boonstra H., Mulder N.H., Aalders J.G., Vries E.G.E. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol. Oncol. 58:1995;165-178.
15. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y F., Foster S.A., Demers G.W., Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2:1996;72-79.